Publications and Presentations

Deep Imputation on Large-Scale Drug Discovery Data

Deep Imputation on Large-Scale Drug Discovery Data

B. W. J. Irwin, T. M. Whitehead, S. Rowland, S. Y. Mahmoud, G. J. Conduit, M. D. Segall, Applied AI Lett., 2021 2(3) p. e31

DOI: 10.1002/ail2.31

This paper outlines practical applications of deep imputation on large-scale drug discovery data. It compares deep learning to traditional QSAR methods. Find out more about deep imputation by visiting our Cerella webpage.

Deep imputation paper


More accurate predictions of the biological properties of chemical compounds would guide the selection and design of new compounds in drug discovery and help to address the enormous cost and low success-rate of pharmaceutical R&D. However this domain presents a significant challenge for AI methods. This is due to the sparsity of compound data and the noise inherent in results from biological experiments. In this paper, we demonstrate how data imputation using deep learning provides substantial improvements over quantitative structure-activity relationship (QSAR) machine learning models that are widely applied in drug discovery. We present the largest-to-date successful application of deep-learning imputation to datasets which are comparable in size to the corporate data repository of a pharmaceutical company (678,994 compounds by 1166 endpoints).

We demonstrate this improvement for three areas of practical application linked to distinct use cases. Firstly, target activity data compiled from a range of drug discovery projects. Secondly, a high value and heterogeneous dataset covering complex absorption, distribution, metabolism and elimination properties. Thirdly, high throughput screening data, testing the algorithm’s limits on early-stage noisy and very sparse data. Achieving median coefficients of determination, R², of 0.69, 0.36 and 0.43 respectively across these applications, the deep learning imputation method offers an unambiguous improvement over random forest QSAR methods, which achieve median R² values of 0.28, 0.19 and 0.23 respectively. We also demonstrate that robust estimates of the uncertainties in the predicted values correlate strongly with the accuracies in prediction, enabling greater confidence in decision-making based on the imputed values.

Download the preprint via the button below or find the final publication on the journal webpage.


Discover Cerella™

Cerella™ is a unique artificial intelligence platform which supports medicinal chemists and other discovery scientists. It escalates success rates and advances small molecule drug discovery, from working with early hits to nominating preclinical candidates. 

Cerella’s AI platform is proven to overcome limitations in drug discovery data, confidently delivering results and seamlessly integrating with your med chem software platforms.